Comparing the Effectiveness of Non-Surgical and Surgical Treatment Modalities in the Management of Oropharyngeal Carcinoma: A Systematic Review and Meta-Analysis
Restricted accessResearch articleFirst published online September, 2021
Comparing the Effectiveness of Non-Surgical and Surgical Treatment Modalities in the Management of Oropharyngeal Carcinoma: A Systematic Review and Meta-Analysis
Objectives: To answer the question, “how effective are nonsurgical treatment modalities compared to any form of surgical intervention (with or without adjunct treatments) in the management of oropharyngeal carcinoma (OPC)?” Data Sources: We conducted systematic searches for Randomized Controlled Trials and Controlled Clinical Trials in PubMed, Cochrane, Ovid Medline, and OpenGrey databases. The US National Institutes of Health Ongoing Trials Register and the World Health Organization International Clinical Trials Registry Platform were also searched for ongoing and past studies. Identified studies were retrieved and assessed for relevance. Review Methods: The primary outcomes assessed in the trials had to include any combination of overall survival, disease-free survival, locoregional control, and recurrence. While secondary outcomes considered were complications of treatment, participants’ satisfaction, costs to participants and health services, and quality of life. Results: Only 5 studies met all inclusion criteria and were selected for qualitative analysis. One compared radiotherapy with surgery, 2 compared chemoradiotherapy with surgery, and 2 compared chemoradiotherapy with transoral robotic surgery. Conclusion: Based on results from this review, surgery is the mainstay of OPC management. However, concurrent chemoradiotherapy is a viable alternative in patients with unresectable disease or disease difficult to access due to location, patients with advanced disease intolerant of surgery, and in patients who do not consent to surgery.
SlootwegPJEvesonJW. Tumours of the oral cavity and oropharynx. In: BarnesLEvesonJWReichartPSidranskyD, eds. Pathology and Genetics of Head and Neck Tumours. 3rd ed.International agency for Research on Cancer, World Health Organization; 2005:166-175. Accessed June 25, 2020. https://screening.iarc.fr/doc/BB9.pdf
2.
TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalA.Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
3.
WinnDMLeeYCHashibeM, et al. The INHANCE Consortium: Toward a Better Understanding of the Causes and Mechanisms of Head and Neck Cancer. vol. 21, Oral Diseases. Blackwell Publishing Ltd; 2015:685-693.
4.
TapiaJLGoldbergLJ.The challenges of defining oral cancer: analysis of an ontological approach. Head Neck Pathol. 2011;5(4):376-384.
5.
ShibaharaT.Oral cancer-diagnosis and therapy. Clin Calcium. 2017;27(10):1427-1433.
6.
HuangSHO’SullivanB.Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18(2):e233-e240.
7.
BernierJCooperJSPajakTF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005;27(10):843-850.
8.
PorcedduS VBresselMPoulsenMG, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018;36:1275-1283.
9.
ShrimeMGGullanePJDawsonL, et al. The impact of adjuvant radiotherapy on survival in T1-2N1 squamous cell carcinoma of the oral cavity. Arch Otolaryngol Head Neck Surg. 2010;136(3):225-228.
10.
PetersLJGoepfertHAngKK, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26(1):3-11.
11.
HigginsJPTThomasJChandlerJCumpstonMLiTPageMJWelchVA (editors). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane; 2021. www.training.cochrane.org/handbook
12.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
ViswanathanMPatnodeCDBerkmanND, et al. Assessing the risk of bias in systematic reviews of health care interventions. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality; 2008.
15.
ViswanathanMBerkmanND.Development of the RTI item bank on risk of bias and precision of observational studies. J Clin Epidemiol. 2012;65(2):163-178.
KramerSGelberRDSnowJB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73–03 of the radiation therapy oncology group. Head Neck Surg. 1987;10(1):19-30.
18.
SangYKRohJLMiRK, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48(5):752-757.
19.
MehannaHMcConkeyCCRahmanJK, et al. PET-NECK: a multicentre randomised phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess. 2017;21(17):1-122.
20.
NicholsACYooJHammondJA, et al. Early-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. Trans-oral robotic surgery (ORATOR) – study protocol for a randomized phase II trial. BMC Cancer. 2013;13:133.
21.
SmithRVSchiffBAGargMHaigentzM.The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients. Laryngoscope. 2015;125(suppl):S1-S15.
22.
RobertsonAGSoutarDSPaulJ, et al. Early closure of a randomized trial: surgery and postoperative radiotherapy versus radiotherapy in the management of intra-oral tumours. Clin Oncol (R Coll Radiol). 1998;10(3):155-160.
23.
StrnadVLotterMKreppnerSFietkauR.Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: long-term results. Strahlenther Onkol. 2015;191(6):495-500.
24.
RudzianskasVInciuraAJuozaityteE, et al. Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy. Acta Otorhinolaryngol Ital. 2012;32(5):297-303.
25.
IyerNGTanDSWTanVKMWangW.Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015;121(10):1599-1607.
26.
BjordalKDe GraeffAFayersPM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H and N35) in head and neck patients. Eur J Cancer. 2000;36(14):1796-807.
27.
FayersPM.Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur J Cancer. 2001;37(11):1331-1334.
28.
ChenAYFrankowshiRBishop-LeoneJ, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: The M. D. Anderson Dysphagia Inventory. Arch Otolaryngol Head Neck Surg. 2001;127(7):870-876.
29.
HowardJMastersonLDwivediRC, et al. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst Rev. 2016;12(12):CD010963.
30.
ParsonsJTMendenhallWMStringerSP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94(11):2967-2980.
31.
BlanchardPBaujatBHolostencoV, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33-40.
32.
YehDHTamSFungK, et al. Transoral robotic surgery vs. Radiotherapy for management of oropharyngeal squamous cell carcinoma – a systematic review of the literature. Eur J Surg Oncol. 2015;41(12):1603-1614.
YouELHenryMZeitouniAG.Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management. Curr Oncol. 2019;26(2):119-123.
35.
GrantSMayo-WilsonEMontgomeryP, et al. CONSORT-SPI 2018 explanation and elaboration: guidance for reporting social and psychological intervention trials. Trials. 2018;19(1):1-18.
